Crawford M H
Acta Pharmacol Toxicol (Copenh). 1985;57 Suppl 2:44-8. doi: 10.1111/j.1600-0773.1985.tb03573.x.
Diltiazem can be effective monotherapy for most patients with chronic stable angina pectoris. The exact mechanism(s) of action of diltiazem for producing a salutary effect in patients with angina pectoris is unknown, but probably involves a reduction in myocardial oxygen demand and an increase in supply via coronary artery dilatation. Administration of less than or equal to 240 mg/day in divided doses uncommonly produces any side effects. Doses of 360 mg/day may be required in some patients. The major adverse effect of high dose therapy is mild pedal oedema. Caution concerning orthostatic hypotension is advised when high dose diltiazem is combined with nitrate therapy or used in patients with poor left ventricular function. Also, diltiazem may potentiate bradycardia or atrio-ventricular block, especially when combined with digitalis preparations or beta-blockers. However, in patients with severe angina, diltiazem may be additive to nitrate and/or beta-blocker therapy.
地尔硫䓬对大多数慢性稳定型心绞痛患者可作为有效的单一疗法。地尔硫䓬在心绞痛患者中产生有益作用的确切作用机制尚不清楚,但可能涉及降低心肌需氧量以及通过冠状动脉扩张增加供血。每日剂量小于或等于240mg分剂量服用时很少产生副作用。一些患者可能需要360mg/天的剂量。高剂量治疗的主要不良反应是轻度足踝水肿。当高剂量地尔硫䓬与硝酸盐类药物联合使用或用于左心室功能较差的患者时,建议注意体位性低血压。此外,地尔硫䓬可能会增强心动过缓或房室传导阻滞,尤其是与洋地黄制剂或β受体阻滞剂合用时。然而,在严重心绞痛患者中,地尔硫䓬可能与硝酸盐类药物和/或β受体阻滞剂疗法具有相加作用。